CN-201 is under clinical development by Curon Biopharmaceutical and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CN-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CN-201 overview

CN-201 is under development for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas including diffuse large B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, mantle cell lymphoma, small lymphocytic lymphoma and transforming large B-cell lymphoma, B-ALL. It is administered through intravenous route. It was also under development for  waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma).

Curon Biopharmaceutical overview

Curon Biopharmaceutical is a clinical-stage innovative biopharmaceutical company focusing on immuno-oncology. It is actively involved in the development of therapies to meet unmet medical needs and offer cancer patients around the world efficient treatment options. The company has developed a pipeline of numerous inventive drug candidates through internal research and collaboration with outside parties. It utilize the unique properties of the tumor microenvironment (TME) to create molecules that can specifically target the TME while causing minimal systemic toxicity. Curon Biopharmaceutical is headquartered in Shanghai, China.

For a complete picture of CN-201’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.